InterWell Health completes $2.4B three-way merger with Fresenius, Cricket Health

InterWell Health has completed its merger with Fresenius Health Partners and Cricket Health in a deal valued at $2.4 billion. The three-way merger was originally announced in March 2022.

The deal brings together three value-based companies providing kidney care services. The combined companies will operate under the InterWell Health brand, and the new company aims to set a standard in kidney care by partnering with a patient's nephrologist and improving care delivery across the care continuum.

The new InterWell Health will leverage its StageSmart machine learning and predictive glomerular filtration rate (GFR) model (known as pGFR) to identify and conduct risk analysis on patients before they reach kidney failure. This model’s 96% accuracy rate will help slow disease progression. InterWell Health will also leverage its patient engagement platform to grow its reach across the country.

"In a value-based world, it is no longer enough just to provide quality care – providers must help patients change behavior, and this requires a fundamental shift in how we engage patients," InterWell Health CEO Robert Sepucha said in a statement. "The new InterWell Health is bringing together cutting-edge data analytics capabilities that identify high-risk patients with the industry's leading patient engagement platform to deliver a rich in-person and virtual experience where they can immerse themselves in information about their disease.

The company currently provides care for 100,000 patients with kidney disease, and by 2025, they expect that figure will grow to 270,000.

Investors Fresenius Medical Care; Valtruis, a WCAS company; Oak HC/FT; Cigna Ventures; and Blue Shield of California are backers in the standalone company.

 

Editor's Note: A previous version of this article stated InterWell Health provides care for 270,000 patients with kidney disease, and by 2025, that figure will grow by 100,000 individuals. The company currently provides care to 100,000 patients, with the expectation to grow to 270,000 patients by 2025. We regret the error.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.